The estimated Net Worth of Warren Whitehead is at least $437 mil dollars as of 21 June 2021. Mr. Whitehead owns over 25,000 units of Aptose Biosciences Inc stock worth over $5,535 and over the last 6 years he sold APTO stock worth over $325,300. In addition, he makes $106,630 as Independent Director at Aptose Biosciences Inc.
Warren has made over 3 trades of the Aptose Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of APTO stock worth $82,750 on 21 June 2021.
The largest trade he's ever made was selling 35,000 units of Aptose Biosciences Inc stock on 23 June 2020 worth over $242,550. On average, Warren trades about 8,000 units every 36 days since 2019. As of 21 June 2021 he still owns at least 15,000 units of Aptose Biosciences Inc stock.
You can see the complete history of Mr. Whitehead stock trades at the bottom of the page.
Warren Whitehead CPA serves as Independent Director of the Company. He has been a Professor of Oncology at the University of Western Ontario since 2008 and a staff medical oncologist at the London Regional Cancer Program since 1990. Dr. Vincent has also served as the cofounder and Chief Executive Officer of Sarissa, Inc., a private company actively involved in the development of compounds which potentiate existing, approved targeted drugs including agents approved in leukemia, since 2000 and has recently been appointed to the Advisory Board of Drug Royalty Corp Toronto. Dr. Vincent holds multiple patents on the potentiation of cancer chemotherapy by the manipulation of drug resistance genes, sits on the advisory boards and speakers panels of several major pharmaceutical companies, and is a frequent international lecturer on the positioning of new drugs in the complex evolving management of lung and gastro-intestinal cancer. Dr. Vincent completed his oncology training at the Royal Marsden Hospital on London, England, with a major focus on leukemia/lymphoma. Dr. Vincent makes valuable contributions to the Board based on over 25 years of experience as a medical oncologist.
As the Independent Director of Aptose Biosciences Inc, the total compensation of Warren Whitehead at Aptose Biosciences Inc is $106,630. There are 9 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
Warren Whitehead is 68, he's been the Independent Director of Aptose Biosciences Inc since 2011. There are 2 older and 10 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
Warren's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger y William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Aptose Biosciences Inc executives and other stock owners filed with the SEC include: